TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
About TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $17.3B
- Net income
- $1.4B
- Total assets
- $40.7B
- Market cap
- $39.8B
- Gross margin
- 51.8%
- Operating margin
- 12.5%
- Net margin
- 8.2%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $17.3B
- Cost of revenue
- $8.3B
- Gross profit
- $8.9B
- Operating expenses
- $6.8B
- Operating income
- $2.2B
- Income tax
- -$180.0M
- Net income
- $1.4B
- EPS (basic)
- $1.23
- EPS (diluted)
- $1.21
Balance sheet
- Total assets
- $40.7B
- Current assets
- $13.9B
- Total liabilities
- $32.8B
- Current liabilities
- $13.5B
- Shareholders’ equity
- $7.9B
Cash flow
- Operating cash flow
- $1.6B
- Investing cash flow
- $737.0M
- Financing cash flow
- -$2.2B
- Net cash flow
- $256.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $39.8B
- P/E ratio
- 25.5
- EPS (diluted)
- $1.21
- Dividend yield
- 1.1%
- Shares outstanding
- 1.3B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 16, 1982
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price
- Profitable — net income of $1.4B in FY2025.
- Revenue grew 9% from FY2021 to FY2025.
- Gross margin of 51.8%, net margin 8.2%.
- Trading 15% below its 52-week high.
- Pays a dividend yielding about 1.1% annually.
- Valued at a price-to-earnings (P/E) ratio of 25.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TEVA PHARMACEUTICAL INDUSTRIES LTD.
Write a review
News about TEVA PHARMACEUTICAL INDUSTRIES LTD
News & sentiment via Polygon.io
Teva Pharmaceutical Industries Ltd: frequently asked questions
Is Teva Pharmaceutical Industries Ltd an American company?
Teva Pharmaceutical Industries Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Teva Pharmaceutical Industries Ltd publicly traded?
Yes — Teva Pharmaceutical Industries Ltd is a publicly traded company. Its stock trades under the ticker symbol TEVA on the NYSE.
What does Teva Pharmaceutical Industries Ltd do?
Teva Pharmaceutical Industries Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
